Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium-Reference-Cited by-同舟云学术

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

Published:2020-07 Issue: Volume:157 Page:104781
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Cappetta Donato,De Angelis Antonella,Ciuffreda Loreta Pia,Coppini Raffaele,Cozzolino Anna,Miccichè Agostino,Dell'Aversana Carmela,D’Amario Domenico,Cianflone Eleonora,Scavone Cristina,Santini Lorenzo,Palandri Chiara,Naviglio Silvio,Crea Filippo,Rota Marcello,Altucci Lucia,Rossi Francesco,Capuano Annalisa,Urbanek Konrad,Berrino Liberato

Funder

Ministero dell'Istruzione, Ministero dell'Università e della Ricerca, Italy

Publisher

Elsevier BV

Subject

Pharmacology

Reference51 articles.

1. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

2. Pharmacological aspects of the safety of gliflozins;Faillie;Pharmacol. Res.,2017

3. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N. Engl. J. Med.,2019

4. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N. Engl. J. Med.,2015

5. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N. Engl. J. Med.,2017

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

2. Inhibition of the RXRA-PPARα-FABP4 signaling pathway alleviates vascular cellular aging by an SGLT2 inhibitor in an atherosclerotic mice model;Science China Life Sciences;2024-08-29

3. SGLT2 inhibitors: how do they affect the cardiac cells;Molecular and Cellular Biochemistry;2024-08-19

4. The effect of sodium-glucose cotransporter type 2 inhibitors on left ventricular diastolic function: current status and prospects;Kardiologiia;2024-07-31

5. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2;Basic Research in Cardiology;2024-07-24